Skip to main content
BCAL DIAGNOSTICS LIMITED logo

BCAL DIAGNOSTICS LIMITED — Investor Relations & Filings

Ticker · BDX ISIN · AU0000160921 ASX Professional, scientific and technical activities
Open in API
Filings indexed 247 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX BDX

About BCAL DIAGNOSTICS LIMITED

https://www.bcaldiagnostics.com

BCAL Diagnostics Limited is focused on the development and commercialization of a non-invasive blood test for the early detection of breast cancer. The company's proprietary diagnostic platform utilizes lipidomics and mass spectrometry to identify specific lipid biomarkers associated with the presence of malignancy. This technology aims to provide a highly accurate, cost-effective, and accessible screening tool that complements or serves as an alternative to traditional mammography. By analyzing changes in the lipid profile of a patient's blood, the test is designed to improve detection rates, particularly in younger women and those with dense breast tissue where conventional imaging may be less effective. The company is dedicated to the clinical validation and global implementation of its screening technology to improve patient outcomes through earlier intervention.

Recent filings

Filing Released Lang Actions
BCAL Launches Early Detection Cancer Platform 2 pages 303.8KB
Regulatory Filings Classification · 82% confidence The document is an ASX announcement providing an operational update on referral infrastructure, digital strategy, telehealth launch, and product rollout. It contains no detailed financial statements, disclosures of voting, dividends, or formal report attachments. It is a general regulatory announcement and does not fit into specific categories like earnings release, capital financing, or management changes. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-05-18 English
BCAL Appoints Anne-Louise Arnett as Chief Executive Officer 4 pages 346.7KB
Board/Management Information Classification · 90% confidence The document is an ASX announcement dated 11 May 2026 detailing the appointment of Anne-Louise Arnett as CEO, the transition of the Executive Chair to Non-Executive Chair, and other leadership changes. This is clearly an announcement of changes in senior management rather than financial results or report publication. Therefore, it fits the Board/Management Information category.
2026-05-10 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 531.1KB
Interim / Quarterly Report Classification · 100% confidence The document is an 'Appendix 4C' filing from the Australian Securities Exchange (ASX), which is a mandatory quarterly cash flow report for listed entities. It includes detailed financial tables (cash flow statements) for the quarter ended 31 March 2026, alongside a narrative 'Quarterly Activities Report' explaining the operational highlights. Since it contains substantive financial data and covers a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2026
2026-04-21 English
BCAL Submits MSAC Application for Avantect Pancreatic Test 3 pages 256.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 31 March 2026 from BCAL Diagnostics Limited. It discusses the submission of an application to the Medical Services Advisory Committee (MSAC) seeking Medicare Benefits Schedule (MBS) reimbursement for a new pancreatic cancer early detection blood test. The content focuses on the application process, clinical evidence, market rollout, and strategic implications of the reimbursement submission. There are no financial statements, detailed financial performance data, or comprehensive management analysis typical of annual or interim reports. The document is a corporate announcement about a significant business development related to reimbursement and market access, which fits best under Capital/Financing Update (CAP) as it relates to funding and commercial rollout strategy. It is not a report publication announcement or regulatory filing as it contains substantive business update information. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-30 English
BCAL Accelerates Rollout of Avantect Early Detection Tests 2 pages 245.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 26 March 2026, describing the commercial rollout of new blood tests by BCAL Diagnostics. It contains no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no merger or acquisition information, and no legal proceedings. The content is a business update about product availability and commercial agreements, typical of a capital or financing update or a general company announcement. The document length is 3626 characters, which is relatively short and does not contain detailed financial data or report content. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Capital/Financing Update (CAP), as it relates to commercial rollout and agreements expanding the company's product availability and market access.
2026-03-25 English
Change of Director's Interest Notice 2 pages 196.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the change (on-market purchase), and dates. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements or company performance data, nor is it an announcement of a report or a certification. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 4036 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement.
2026-03-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.